Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
Erminia Massarelli
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
J. Jack Lee
No relevant relationships to disclose
Adam S. Garden
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; MedImmune
Research Funding - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; MedImmune; Merck; Novartis; Xcovery
William N. William
No relevant relationships to disclose
Roy B. Tishler
No relevant relationships to disclose
Bonnie S. Glisson
No relevant relationships to disclose
Kathryn A. Gold
No relevant relationships to disclose
Faye M. Johnson
No relevant relationships to disclose
Lawrence E. Ginsberg
No relevant relationships to disclose
Michelle D. Williams
No relevant relationships to disclose
Jeffrey Myers
No relevant relationships to disclose
Merrill S. Kies
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
No relevant relationships to disclose